

2021 Annual General Meeting – Questions and Answers

Ergomed plc held its 2021 Annual General Meeting (“**AGM**”) on 10 June 2021. In order to comply with the UK government’s measures to limit the spread of COVID-19, and to ensure the safety of the Company’s shareholders and the wider community, the AGM was run as a closed meeting.

The Board regards the AGM as an important opportunity to engage with shareholders and therefore encouraged shareholders to submit questions before the AGM. Questions received, and our response, are set out below.

Question: Do you have any plans to review the gender diversity of your Board in the near future?

Answer: *Ergomed’s Board of Directors recognises that increasing diversity, including gender diversity, is an important factor in ensuring effective decision-making and stakeholder representation. The Board supports improved gender balance as an important goal, whilst acknowledging that the current composition of the Board does not reflect this.*

Given the size of Ergomed’s Board, and the company’s stage of development, our aim is to ensure that the best possible mix of skills, experience and capabilities is represented in our decision-making processes, in order to support Ergomed’s long-term growth. This is reflected in the recent appointments of Dr. Llew Keltner and Mark Enyedy, both of whom are US-based, as independent non-executive directors.

We are proud to report that, across the Ergomed group, 58% of management positions are occupied by women. We will continue to support improved gender diversity at Board level as and when any new Board appointments are considered.